All In Biotech

Drug Trial Radar · NCT05003804

Allergic Disease Onset Prevention Study

A Phase 1b/2, Randomized, Double-blind, Placebo-controlled, Multi-center Study of STMC-103H in Neonates and Infants at Risk for Developing Allergic Disease

Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 283 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

283

Actual

Start

Sep 1, 2021

Primary completion

Nov 26, 2024

Study completion Oct 21, 2025

Sponsor

Lead sponsor
Siolta Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 0 days, up to 14 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-103H in neonates and infants at risk for developing allergic disease (Type 1 hypersensitivity). Subjects will be enrolled in a three-part sequential approach. Participants in the safety-run portion of the study (Part A1: 1 year to \<6 years of age and A2: 1 month to \<12 months of age) will receive 28 days of treatment with STMC-103H or placebo, followed by 28 days of follow-up. A Data and Safety Monitoring Committee (DSMC) will review safety data after all patients in each part complete 28 days of therapy prior to enrolling the next part. After A2, Part B will enroll 224 patients for 336 days of treatment with STMC-103H or placebo, followed by 336 days of follow-up. Stool, blood, and optional samples will be collected in Parts A2 and part B. Primary safety endpoints are frequency, type and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), as well as findings on physical exams, vitals, and safety laboratories. The primary efficacy endpoint is incidence of physician-diagnosed atopic dermatitis at day 336.

Conditions

  • Atopic Dermatitis
  • Type 1 Hypersensitivity

Interventions

  • STMC-103HBiological

    STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria

  • PlaceboBiological

    Powder containing excipients found in STMC-103H: magnesium stearate, mannitol and silicon dioxide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A1 and A2: Assess safety and tolerability of STMC-103H in children and infants at risk for development of allergic disease by assessing adverse events (AE), serious adverse events (SAE), and AEs of special interestTime frame: Through 56 days of study
  2. Part B: Assess the safety, tolerability of STMC-103H in neonate and infants subjects at risk for development of atopic disease by monitoring AEs, SAEs, AESI, physical exam findings, and clinical safety laboratories.Time frame: Through 672 days of study
  3. Part B: Primary Efficacy Endpoint: Incidence of physician-diagnosed atopic dermatitis at 336 daysTime frame: Day 336

Locations

31 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Arizona Health Sciences

    Tucson, Arizona

  • Arkansas Children's Research Institute

    Little Rock, Arkansas

  • UCLA Health

    Los Angeles, California

  • Rady Children's Hospital - San Diego

    San Diego, California

  • UCSF Benioff Children's Hospital

    San Francisco, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Children's Healthcare of Atlanta

    Atlanta, Georgia

  • Lurie Children's Hospital

    Chicago, Illinois

  • University of Chicago Medicine

    Chicago, Illinois

  • Riley Children's Health at University of Indiana

    Indianapolis, Indiana

  • Johns Hopkins University School of Medicine

    Baltimore, MD, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • University of Michigan Health

    Ann Arbor, Michigan

  • Northwell Healthcare

    Great Neck, New York

  • NYU Langone Fink Children's

    New York, New York

  • Mt. Sinai Jaffe Allergy Institute

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Cincinnati Children's Hospital

    Cincinnati, Ohio

  • Tribe Clinical Research

    Greenville, South Carolina

  • Coastal Pediatrics Research

    Summerville, South Carolina

  • Dell Medical School at UT Austin

    Austin, Texas

  • UT Southwestern/Children's Health

    Dallas, Texas

  • Seattle Allergy and Asthma Research Institute

    Seattle, Washington

  • Univ. of Wisconsin-Madison/Jackson Research Group

    Madison, Wisconsin

  • The Children's Hospital at Westmead

    Westmead, New South Wales, Australia

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia

  • The Women's and Children's Hospital

    Adelaide, South Australia, Australia

  • Monash Children's Hospital

    Clayton, Victoria, Australia

  • Murdoch Children's Research Institute

    Parkville, Victoria, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • Centro de Neumologia Pediatrica

    Caguas, Puerto Rico, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.